MTRNR2L2

Across TCGA pan-cancer cohorts, MTRNR2L2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MTRNR2L2’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where MTRNR2L2 RNA is repressed in tumor relative to normal tissue. In most cancer types MTRNR2L2 is over-expressed in tumor, although a few such as UCEC and COAD show the opposite, repressed pattern.

UCEC, COAD, and HNSC are the cancer types where MTRNR2L2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTRNR2L2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	II,III,IV	−0.769	.012	6	view →
COAD	All	All	−0.501	<.001	4	view →
HNSC	Male	IV	−0.416	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MTRNR2L2–UCEC

Open the UCEC breakdown →